Global CDKL5 Deficiency Disorder (CDD) Epidemiology Forecast Report 2017-2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "CDKL5 Deficiency Disorder (CDD) - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

The 'CDKL5 Deficiency Disorder (CDD) - Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical and forecasted CDD epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

CDKL5 Deficiency Disorder (CDD) Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalence of CDD, Diagnosed Prevalence of CDD, Gender-specific Diagnosed Prevalence of CDD and clinical characteristics of CDD, a scenario of CDD in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

CDD Detailed Epidemiology Segmentation

• In the 7MM, the total prevalent population of CDD was estimated to be 16,397 cases in 2017.
• The total diagnosed prevalent population of CDD in the seven major markets was 3,584 in 2017, which is expected to increase in the forecast period
• In 2017, the total diagnosed prevalence of CDD in the United States was 208 in males and 1,315 in females
• There are several types of clinical characteristics of CDD, among which, mainly eight types of characteristics are frequently observed. As per the estimates 1,234, 716, 1,142, 1,218, 1,317, 1,080, 976, 1,295, patients were affected by epileptic spasms, hypsarrhythmia, cortical visual impairment, hand stereotypies, gastrointestinal symptoms, constipation, reflux, and sleep difficulties in 2017.

Scope of the Report

• The report covers the descriptive overview of CDD, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of CDD.
• The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of CDD, Total Diagnosed and Treated Cases of CDD.

Report Highlights

• Eleven-Year Forecast of CDD
• 7MM Coverage
• Prevalence of CDD in 7MM
• Diagnosed Prevalence of CDD in 7MM
• Gender-specific Diagnosed Prevalence of CDD
• Clinical Characteristics of CDD

Key Questions Answered

• What is the disease risk, burden and unmet needs of CDD?
• What is the historical CDD patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of CDD at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to CDD?
• Out of the countries mentioned above, which country would have the highest prevalent population of CDD during the forecast period (2020-2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Key Topics Covered:

1 Key Insights

2 Executive Summary

3 SWOT Analysis

4 CDKL5 Deficiency Disorder (CDD) Market Overview at a Glance

4.1 Patient Share (%) Distribution of CDKL5 Deficiency Disorder (CDD) in 2017

4.2 Patient Share (%) Distribution of CDKL5 Deficiency Disorder (CDD) in 2030

5 Disease Background and Overview: CDKL5 Deficiency Disorder (CDD)

5.1 Introduction

5.2 Signs and Symptoms of CDD

5.2.1 Focal Seizures

5.2.2 Generalized Seizures

5.3 Inheritance Pattern

5.4 Causes of CDD

5.5 Difference between Rett Syndrome and CDD

5.6 Signaling Mechanism of CDD

5.7 Biomarkers for CDD

5.8 Diagnosis of CDD

5.8.1 Genetic Tests for CDKL5 Variants

5.9 Differential Diagnosis

6 Recognized Establishments

7 Treatment

7.1.1 Antiepileptic drugs/medications (AEDs)

7.1.2 Steroid Treatment

7.1.3 Ketogenic Diet

7.1.4 Neuro-surgery

7.1.5 Vagal Nerve Stimulation (VNS)

7.2 Therapeutic Interventions

7.2.1 Physical therapy/Physiotherapy

7.2.2 Occupational Therapy

7.2.3 Neurological Speech Therapy

7.2.4 Music Therapy

7.2.5 Hippotherapy/Equine Therapy

7.2.6 Hydrotherapy

7.2.7 Massage Therapy

7.2.8 Vision Therapy

7.2.9 Health and Social Care

8 Epidemiology and Patient Population

8.1 Key Findings

8.2 Epidemiology Methodology

9 Total Prevalent Population of CDKL5 Deficiency Disorder (CDD) in the 7MM

10 Total Diagnosed Prevalent Population of CDD in the 7MM

11 Epidemiology of CDLK5 Deficiency Disorder (CDD) in the 7MM

11.1.1 Assumptions and Rationale

11.1 United States

11.1.1 Prevalence of CDD in the United States

11.1.2 Diagnosed Prevalence of CDD in the United States

11.1.3 Gender-specific Diagnosed Prevalence of CDD in the United States

11.1.4 Clinical Characteristics of CDD in the United States

11.2 Germany

11.3 France

11.4 Italy

11.5 Spain

11.6 United Kingdom

11.7 Japan

12 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/g6x8mo